Press Releases

September 3, 2019
BOSTON , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Simon Harford, Chief Financial Officer, will present at the 21 st Annual Rodman & Renshaw Global
August 8, 2019
— Odevixibat Phase 3 PEDFIC 1 topline results expected mid-2020 — — Initiated elobixibat Phase 2 trial in NAFLD/NASH — — Management to host conference call and webcast today at 10 a.m. EDT — BOSTON , Aug. 08, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc.
August 6, 2019
BOSTON , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the Wedbush PacGrow Healthcare
July 9, 2019
— Expects Odevixibat PEDFIC 1 Phase 3 Topline Data Mid-2020 — — Site Activated for Odevixibat PEDFIC 2 Expanded Open-Label Cohort — — Odevixibat Biliary Atresia Pivotal Trial Expected to Begin in 2020 — — Moves Into NASH with Initiation of Elobixibat Phase 2 trial — BOSTON , July 09, 2019 (GLOBE
June 20, 2019
New Initiative to Create Awareness and Understanding of Life-Threatening Pediatric Liver Disease  Announced new PFIC Voices website, www.PFICvoices.com BOSTON , June 20, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing
May 29, 2019
BOSTON , May 29, 2019 (GLOBE NEWSWIRE) -- Albireo Pharma , Inc. (Nasdaq: ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive Officer, will present at the following investor conferences
May 9, 2019
Odevixibat Phase 3 PEDFIC 1 PFIC trial continues to enroll as planned Initiation of additional cohort of PFIC patients in PEDFIC 2 extension trial announced Odevixibat pivotal trial in biliary atresia on track to begin H2 2019 IND cleared to initiate elobixibat Phase 2 trial in NASH Q2 2019